Neurizon

Governance

Updates

Announcements

Home

Space Grotesk

Tylah Tully chats with Neurizon Therapeutics (ASX:NUZ) managing director Dr Michael Thurn after the FDA has delayed its review of the company’s response to the NUZ-001 clinical hold until October 3rd.

Thurn assures investors the delay is not due to the submission or drug candidate, but rather capacity constraints of the FDA.

While disappointed, the company remains confident in NUZ-001’s potential and is working with US neurologists, key opinion leaders, and patient groups to advocate for a faster review.

August 2025 – Stockhead Long Shortz: Strong confidence remains as FDA review delayed